Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 12/20 | 0.51 |
| ▸ | CRHBP | P24387 | 2/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | RORA | P35398 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168108 | 0.81 | PSIP1 (0.48) | RORCALDH1A1GAA | |
| SCHEMBL2049579 | 0.78 | ALDH1A1 (0.66) | CRHBPCRHR2ALDH1A1LMNAHTT | |
| SCHEMBL23174362 | 0.73 | PSIP1 (0.47) | RORCKCNH2RORAALDH1A1GAA | |
| SCHEMBL23174361 | 0.73 | ESR1 (0.45) | RORCKCNH2RORACA1CA2 | |
| SCHEMBL28247832 | 0.72 | GAA (0.46) | RORCKCNH2RORAALDH1A1CA1 | |
| SCHEMBL2656833 | 0.72 | ALDH1A1 (0.44) | CRHBPCRHR2ALDH1A1LMNAHTT | |
| SCHEMBL23174343 | 0.72 | ESR1 (0.44) | RORCKCNH2CA1CA2GAA | |
| SCHEMBL28113455 | 0.72 | RORC (0.52) | RORCCRHBPCRHR2KCNH2RORA | |
| SCHEMBL15146926 | 0.72 | HPGD (0.58) | CRHBPCRHR2ALDH1A1LMNAHTT | |
| SCHEMBL19987486 | 0.71 | PSIP1 (0.52) | RORCRORAALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118698-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118698-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | APLNR, APMAP, EDNRA | RORC 2141/4885CRHBP 395/4885CRHR2 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.